A citation-based method for searching scientific literature

Soo Heon Kwak, You-Cheol Hwang, Jong Chul Won, Ji Cheol Bae, Hyun Jin Kim, Sunghwan Suh, Eun Young Lee, Subin Lee, Sang-Yong Kim, Jae Hyeon Kim. Diabetes Obes Metab 2020
Times Cited: 9







List of co-cited articles
46 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Role of continuous glucose monitoring for type 2 in diabetes management and research.
Robert Vigersky, Maneesh Shrivastav. J Diabetes Complications 2017
47
33

The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Gyuri Kim, Sewon Oh, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim, Moon-Kyu Lee. Expert Opin Pharmacother 2017
16
33

Mean amplitude of glycemic excursions, a measure of diabetic instability.
F J Service, G D Molnar, J W Rosevear, E Ackerman, L C Gatewood, W F Taylor. Diabetes 1970
831
33

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
Julian P T Higgins, Douglas G Altman, Peter C Gøtzsche, Peter Jüni, David Moher, Andrew D Oxman, Jelena Savovic, Kenneth F Schulz, Laura Weeks, Jonathan A C Sterne. BMJ 2011
33

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.
Bo Ahrén, Anja Schweizer, Sylvie Dejager, Beth E Dunning, Peter M Nilsson, Margaretha Persson, James E Foley. J Clin Endocrinol Metab 2009
136
22

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
22


Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.
Louis Monnier, Emilie Mas, Christine Ginet, Françoise Michel, Laetitia Villon, Jean-Paul Cristol, Claude Colette. JAMA 2006
22

Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Ayako Fuchigami, Fumika Shigiyama, Toru Kitazawa, Yosuke Okada, Takamasa Ichijo, Mariko Higa, Toru Hiyoshi, Ikuo Inoue, Kaoru Iso, Hidenori Yoshii,[...]. Cardiovasc Diabetol 2020
28
22

Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).
Kyu Yong Cho, Hiroshi Nomoto, Akinobu Nakamura, Shinichiro Kawata, Hajime Sugawara, Jun Takeuchi, So Nagai, Kazuhisa Tsuchida, Kazuno Omori, Hiroki Yokoyama,[...]. Diabetes Obes Metab 2020
7
28

Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naïve Japanese patients with type 2 diabetes mellitus.
Ryo Suzuki, Jun-Ichi Eiki, Takashi Moritoyo, Kenichi Furihata, Akira Wakana, Yukari Ohta, Shigeru Tokita, Takashi Kadowaki. Diabetes Obes Metab 2018
4
50

Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
Seiichi Tanaka, Kunihiro Suzuki, Chie Aoki, Mai Niitani, Kanako Kato, Takanori Tomotsune, Yoshimasa Aso. Diabetes Technol Ther 2014
17
22


Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Bo Ahrén, James E Foley, Ele Ferrannini, David R Matthews, Bernard Zinman, Sylvie Dejager, Vivian A Fonseca. Diabetes Care 2010
67
22

Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.
Yutaka Mori, Yukiko Taniguchi, Shigeru Miyazaki, Junichi Yokoyama, Kazunori Utsunomiya. Diabetes Technol Ther 2013
19
22

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.
V Fonseca, A Schweizer, D Albrecht, M A Baron, I Chang, S Dejager. Diabetologia 2007
289
22

Effects of Vildagliptin Add-on Insulin Therapy on Nocturnal Glycemic Variations in Uncontrolled Type 2 Diabetes.
Feng-Fei Li, Yun Shen, Rui Sun, Dan-Feng Zhang, Xing Jin, Xiao-Fang Zhai, Mao-Yuan Chen, Xiao-Fei Su, Jin-Dan Wu, Lei Ye,[...]. Diabetes Ther 2017
7
28

Efficacy of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion (CSII) in Hospitalized Patients with Type 2 Diabetes.
Fu-Ping Lyu, Bing-Kun Huang, Wei-Juan Su, Fang-Fang Yan, Jin-Yang Zeng, Zheng Chen, Yu-Xian Zhang, Shun-Hua Wang, Yin-Xiang Huang, Mu-Lin Zhang,[...]. Diabetes Ther 2020
2
100

Glycemic Variability: How Do We Measure It and Why Is It Important?
Sunghwan Suh, Jae Hyeon Kim. Diabetes Metab J 2015
151
22


Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report.
Daisuke Matsutani, Masaya Sakamoto, Hiroyuki Iuchi, Souichirou Minato, Hirofumi Suzuki, Yosuke Kayama, Norihiko Takeda, Ryuzo Horiuchi, Kazunori Utsunomiya. Cardiovasc Diabetol 2018
23
22

Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes.
Jingyi Lu, Xiaojing Ma, Jian Zhou, Lei Zhang, Yifei Mo, Lingwen Ying, Wei Lu, Wei Zhu, Yuqian Bao, Robert A Vigersky,[...]. Diabetes Care 2018
150
22

Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study.
Seung-Hwan Lee, Kyung-Wan Min, Byung-Wan Lee, In-Kyung Jeong, Soon-Jib Yoo, Hyuk-Sang Kwon, Yoon-Hee Choi, Kun-Ho Yoon. Diabetes Metab J 2021
4
50

Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: an analysis of 480 subjects.
Sang-Man Jin, Tae-Hun Kim, Ji Cheol Bae, Kyu Yeon Hur, Myung-Shik Lee, Moon-Kyu Lee, Jae Hyeon Kim. Diabetes Res Clin Pract 2014
37
22

The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading.
Roy W Beck, Crystal G Connor, Deborah M Mullen, David M Wesley, Richard M Bergenstal. Diabetes Care 2017
149
22



Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
Sang Youb Han, Sun Ae Yoon, Byoung Geun Han, Sung Gyun Kim, Young-Il Jo, Kyung Hwan Jeong, Kook-Hwan Oh, Hyeong Cheon Park, Sun-Hee Park, Shin-Wook Kang,[...]. Diabetes Obes Metab 2018
3
66

Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).
Sun A Yoon, Byoung G Han, Sung G Kim, Sang Y Han, Young I Jo, Kyung H Jeong, Kook H Oh, Hyeong C Park, Sun H Park, Shin W Kang,[...]. Diabetes Obes Metab 2017
11
22

A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.
S J Yang, K W Min, S K Gupta, J Y Park, V K Shivane, S U Pitale, P K Agarwal, A Sosale, P Gandhi, M Dharmalingam,[...]. Diabetes Obes Metab 2013
42
22

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus.
Sung-Ho Kim, Jung-Hwa Yoo, Woo Je Lee, Cheol-Young Park. Diabetes Metab J 2016
25
22

Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Sung-Ho Kim, Eunsoo Jung, Min Kyung Yoon, O Hwan Kwon, Dal-Mi Hwang, Dong-Wook Kim, Junghyun Kim, Sun-Mee Lee, Hyeon Joo Yim. Eur J Pharmacol 2016
15
22

Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).
Se E Park, Byung W Lee, Jae H Kim, Woo J Lee, Jae H Cho, Chang H Jung, Seung H Lee, Sunghwan Suh, Gwong C Hur, Sung H Kim,[...]. Diabetes Obes Metab 2017
19
22

A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone.
Chan-Hee Jung, Eun-Jung Rhee, Won-Young Lee, Kyung Wan Min, Vyankatesh K Shivane, Aravind R Sosale, Hak Chul Jang, Choon Hee Chung, Il Seong Nam-Goong. Diabetes Obes Metab 2018
2
100

Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
Soo Lim, Kyung Ah Han, JaeMyung Yu, Parinya Chamnan, Eun Sook Kim, Kun-Ho Yoon, Sam Kwon, Min Kyong Moon, Kwan Woo Lee, Dong-Jun Kim,[...]. Diabetes Obes Metab 2017
12
22

A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
E J Rhee, W Y Lee, K H Yoon, S J Yoo, I K Lee, S H Baik, Y K Kim, M K Lee, K S Park, J Y Park,[...]. Diabetes Obes Metab 2010
34
22

Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444).
J H Shon, N Kim, S J Park, M K Oh, E Y Kim, S H Lee, Y H Kim, J G Shin. Diabetes Obes Metab 2014
13
22


Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).
Young Min Cho, Chaicharn Deerochanawong, Samroeng Seekaew, Swangjit Suraamornkul, Sunun Benjachareonwong, Sarinya Sattanon, Parinya Chamnan, Thanitha Sirirak, Natapong Kosachunhanun, Thongchai Pratipanawatr,[...]. Diabetes Obes Metab 2020
2
100

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
I M Stratton, A I Adler, H A Neil, D R Matthews, S E Manley, C A Cull, D Hadden, R C Turner, R R Holman. BMJ 2000
22


Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial.
Ting-Ting Yin, Yan Bi, Ping Li, Shan-Mei Shen, Xiao-Lu Xiong, Li-Jun Gao, Can Jiang, Yan Wang, Wen-Huan Feng, Da-Long Zhu. Diabetes Ther 2018
10
22

A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin.
Hiroshi Nomoto, Hideaki Miyoshi, Hajime Sugawara, Kota Ono, Shingo Yanagiya, Mayuko Oita, Akinobu Nakamura, Tatsuya Atsumi. Diabetol Metab Syndr 2017
22
22

Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial.
Juan P Frías, Samer Nakhle, James A Ruggles, Sergey Zhuplatov, Eric Klein, Rong Zhou, Poul Strange. Diabetes Obes Metab 2017
18
22

Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
Robert R Henry, Poul Strange, Rong Zhou, Jeremy Pettus, Leon Shi, Sergey B Zhuplatov, Traci Mansfield, David Klein, Arie Katz. Diabetes Technol Ther 2018
27
22

International Consensus on Use of Continuous Glucose Monitoring.
Thomas Danne, Revital Nimri, Tadej Battelino, Richard M Bergenstal, Kelly L Close, J Hans DeVries, Satish Garg, Lutz Heinemann, Irl Hirsch, Stephanie A Amiel,[...]. Diabetes Care 2017
617
22

Hypoglycemia in diabetic patients undergoing chronic hemodialysis.
Chiao-Yin Sun, Chin-Chan Lee, Mai-Szu Wu. Ther Apher Dial 2009
12
11

High Hemoglobin A1c levels and glycemic variability increase risk of severe hypoglycemia in diabetic hemodialysis patients.
Mark E Williams, Rajesh Garg, Weiling Wang, Ronilda Lacson, Franklin Maddux, Eduardo Lacson. Hemodial Int 2014
11
11


Hypoglycemia-associated autonomic failure in advanced type 2 diabetes.
Scott A Segel, Deanna S Paramore, Philip E Cryer. Diabetes 2002
198
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.